Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.46 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.46 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3430946 | 1.00 | MEN1 (0.48) | MEN1KMT2ANPC1GRIN1GRIN2B | |
| SCHEMBL3430941 | 1.00 | MEN1 (0.48) | MEN1KMT2ANPC1GRIN1GRIN2B | |
| SCHEMBL13747864 | 0.92 | MEN1 (0.48) | MEN1KMT2ANPC1GRIN1GRIN2B | |
| SCHEMBL13616146 | 0.92 | MEN1 (0.48) | MEN1KMT2ANPC1GRIN1GRIN2B | |
| SCHEMBL13630621 | 0.92 | MEN1 (0.48) | MEN1KMT2ANPC1GRIN1GRIN2B | |
| SCHEMBL13747718 | 0.92 | MEN1 (0.48) | MEN1KMT2ANPC1GRIN1GRIN2B | |
| SCHEMBL13616134 | 0.92 | MEN1 (0.48) | MEN1KMT2ANPC1GRIN1GRIN2B | |
| SCHEMBL3402948 | 0.92 | MEN1 (0.48) | MEN1KMT2ANPC1GRIN1GRIN2B | |
| SCHEMBL13616316 | 0.92 | MEN1 (0.48) | MEN1KMT2ANPC1GRIN1GRIN2B | |
| SCHEMBL3402943 | 0.92 | MEN1 (0.48) | MEN1KMT2ANPC1GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275538-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | UNIVERSITE LAVAL (CA) | 2009-11-05 | — | — | US | disclosed |
| WO-2009097695-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | CHLORION PHARMA, INC. (CA) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275538-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | OPRL1, OPRK1, AHR | MEN1 4697/4885KMT2A 1752/4885NPC1 2712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.